Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast 2025-2034

Amyotrophic lateral sclerosis (ALS) is of two types: sporadic ALS and familial ALS. Sporadic ALS comprises approximately 90% of all ALS cases whereas familial ALS accounts for around 10% of ALS cases. Symptoms of the disease usually develop between the ages of 55 and 75.

Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report Coverage

The “Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of amyotrophic lateral sclerosis (ALS). It projects the future incidence and prevalence rates of amyotrophic lateral sclerosis (ALS) across various populations. The study covers age, gender, and type as major determinants of the amyotrophic lateral sclerosis (ALS)-affected population. The report highlights patterns in the prevalence of amyotrophic lateral sclerosis (ALS) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of amyotrophic lateral sclerosis (ALS) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Amyotrophic Lateral Sclerosis (ALS): Disease Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, refers to a progressive neurodegenerative disorder that impacts nerve cells in the brain and spinal cord. ALS is characterized by the gradual degeneration of motor neurons, which are responsible for controlling voluntary muscles. As the disease progresses, patients experience muscle wasting, difficulty speaking and swallowing, and eventually, respiratory failure.

Amyotrophic Lateral Sclerosis (ALS): Treatment Overview

The treatment approach generally involves a combination of medications, physical therapy, respiratory support, and nutritional care. Riluzole, an FDA-approved drug for ALS, has been shown to slightly slow disease progression by reducing glutamate levels in the brain. Edaravone helps in slowing the decline in physical function in some individuals with ALS. To manage symptoms like muscle cramps, spasticity, or pain, healthcare providers may prescribe muscle relaxants, pain relievers, or other supportive drugs.

Epidemiology

The amyotrophic lateral sclerosis (ALS) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for amyotrophic lateral sclerosis (ALS) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for amyotrophic lateral sclerosis (ALS) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In the United States, the annual incidence is reported to be 2 to 3 cases per 100,000 population.
• Studies suggest that men are slightly more likely to develop amyotrophic lateral sclerosis compared to women although the frequency of occurrence becomes equal in older adults.
• The mean age of onset of sporadic amyotrophic lateral sclerosis is estimated to be 65 years whereas familial amyotrophic lateral sclerosis has 46 to 55 years as the mean age of onset.
• Genetic changes or variants may contribute to ALS in nearly 70% of familial cases and about 5% to 10% of sporadic ALS cases. Additionally, more than 40 genes have been identified as being associated with ALS.

Country-wise Amyotrophic Lateral Sclerosis (ALS) Epidemiology

The amyotrophic lateral sclerosis (ALS) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of amyotrophic lateral sclerosis (ALS) varies between countries, owing to differences in genetic factors, environmental exposures, healthcare access, and diagnostic practices. Variations in lifestyle, diet, industrial exposure, and healthcare infrastructure can influence the incidence and prevalence of ALS. In the United States, around 5,000 individuals receive an amyotrophic lateral sclerosis diagnosis annually.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of amyotrophic lateral sclerosis (ALS) based on several factors.
• Amyotrophic Lateral Sclerosis (ALS) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of amyotrophic lateral sclerosis (ALS) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of amyotrophic lateral sclerosis (ALS) epidemiology in the 8 major markets?
• What will be the total number of patients with amyotrophic lateral sclerosis (ALS) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of amyotrophic lateral sclerosis (ALS) in the 8 major markets in the historical period?
• Which country will have the highest number of amyotrophic lateral sclerosis (ALS) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of amyotrophic lateral sclerosis (ALS) during the forecast period of 2025-2034?
• What are the currently available treatments for Amyotrophic Lateral Sclerosis (ALS)?
• What are the disease risks, signs, symptoms, and unmet needs of amyotrophic lateral sclerosis (ALS)?

This product will be delivered within 3-5 business days.